The Alzheimer's drugs market size is expected to grow from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031; it is projected to register a CAGR of 13.6% during 2025-2031. The aging population & rising Alzheimer's prevalence, and improved diagnostics & early detection are noteworthy factors contributing to the expansion of the Alzheimer's drugs market size. However, the high cost of disease-modifying therapies hinders the Alzheimer's drugs market.
Public-private partnerships and funding leverage the resources of government organizations, academic centers, pharmaceutical firms, and philanthropic foundations to speed up the creation of effective treatments. The US National Institutes of Health (NIH)'s Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD 2.0) has attracted a substantial number of resources to drive research on Alzheimer's. This initiative integrates more than US$61 million of public investment from the NIH with investment from pharmaceutical firms like Eisai and Takeda. This project promotes open sharing of data and precision medicine strategies, accelerating biomarker discovery and validation of therapeutic targets. Philanthropic initiatives like BrightFocus and Part the Cloud have invested millions in early-stage research, backing forward-thinking projects which have secured more than a billion dollars in funding from multiple sources, ranging from venture capital to pharma partnerships. At the state level, the proposed Texas Dementia Prevention and Research Institute of Texas (DPRIT) would commit up to US$3 billion over ten years to dementia research, fostering collaborations that might spur local biotech expansion and clinical breakthroughs. Furthermore, partnerships among big pharma and biotechs are on the rise, such as with Biogen in partnership with Eisai to co-develop and market Alzheimer's therapies, pooling resources and capabilities to drive faster entry into markets. These public-private initiatives mitigate financial risks and enhance resource sharing, de-risking drug development, and compress timelines. Commercially, they diversify the Alzheimer's drugs pipeline, stimulate investment from biotech and pharma, and boost regulatory and public trust in new medicines. These partnerships and funding influxes are accelerating disease-modifying treatments and underpinning a more innovation-driven Alzheimer's drugs market.
End User-Based Insights
Based on end user, the Alzheimer's drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest Alzheimer's drugs market share in 2024. Particularly in areas where hospital-based care is the main method of diagnosis and treatment initiation, hospital pharmacies distribute and oversee AD medications. Hospital pharmacies are essential resources for prescribing, dispensing, and advising patients and caregivers on therapeutic options due to the complexity of managing Alzheimer's disease, which calls for specialized neurologists or geriatricians. The sale of Alzheimer's medications in hospital pharmacies is influenced by reimbursement regulations and changing treatment recommendations. Hospitals continue to prescribe ChEIs as the first-line symptomatic treatments for mild to moderate AD. Because of its demonstrated effectiveness and tolerability, donepezil (Aricept), the most prescribed ChEI worldwide, is included in hospital formularies. Rivastigmine provides the dosing flexibility preferred in hospital settings where patient monitoring is practical. It is available as oral capsules and transdermal patches. Hospital pharmacies add value by providing medication counseling, adherence monitoring, and managing side effects-services critical in Alzheimer's treatment. Such programs differentiate hospital pharmacy offerings from retail outlets and support patient outcomes, potentially driving demand for specific formulations (e.g., rivastigmine patches for better compliance), thereby fueling the Alzheimer's drugs market growth.
The World Health Organization and Medicare are among the primary and secondary sources referred to while preparing the Alzheimer's drugs market report.
TABLE OF CONTENTS
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Analyst Market Outlook
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
3.3 Assumptions and Limitations
4. Alzheimer's Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Alzheimer's Drugs Market – Key Market Dynamics
5.1 Alzheimer's Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Aging Population & Rising Alzheimer's Prevalence
5.2.2 Improved Diagnostics & Early Detection
5.3 Market Restraints
5.3.1 High Cost of Disease-Modifying Therapies (DMTs)
5.4 Market Opportunities
5.4.1 Combination Therapies and Adjunct Treatments
5.5 Future Trends
5.5.1 Public-Private Collaborations and Funding Growth
5.6 Impact of Drivers and Restraints:
6. Alzheimer's Drugs Market – Global Market Analysis
6.1 Alzheimer's Drugs Market Revenue (US$ Million), 2021–2031
6.2 Alzheimer's Drugs Market Forecast Analysis
7. Alzheimer's Drugs Market Analysis – by Drug Class
7.1 Cholinesterase Inhibitors
7.1.1 Overview
7.1.2 Cholinesterase Inhibitors: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 NMDA Receptor Antagonists
7.2.1 Overview
7.2.2 NMDA Receptor Antagonists: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Combination Drugs
7.3.1 Overview
7.3.2 Combination Drugs: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8. Alzheimer's Drugs Market Analysis – by End User
8.1 Hospital Pharmacies
8.1.1 Overview
8.1.2 Hospital Pharmacies: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Retail Pharmacies
8.2.1 Overview
8.2.2 Retail Pharmacies: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Online Pharmacies
8.3.1 Overview
8.3.2 Online Pharmacies: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9. Alzheimer's Drugs Market – Geographical Analysis
9.1 Overview
9.2 North America
9.2.1 North America Alzheimer's Drugs Market Overview
9.2.2 North America: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
9.2.2.1 North America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Drug Class
9.2.2.1.1 North America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Cholinesterase Inhibitors
9.2.2.2 North America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by End User
9.2.3 North America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Country
9.2.3.1 United States: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2.3.1.1 United States: Alzheimer's Drugs Market Breakdown, by Drug Class
9.2.3.1.1.1 United States: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.2.3.1.2 United States: Alzheimer's Drugs Market Breakdown, by End User
9.2.3.2 Canada: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2.3.2.1 Canada: Alzheimer's Drugs Market Breakdown, by Drug Class
9.2.3.2.1.1 Canada: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.2.3.2.2 Canada: Alzheimer's Drugs Market Breakdown, by End User
9.2.3.3 Mexico: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2.3.3.1 Mexico: Alzheimer's Drugs Market Breakdown, by Drug Class
9.2.3.3.1.1 Mexico: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.2.3.3.2 Mexico: Alzheimer's Drugs Market Breakdown, by End User
9.3 Europe
9.3.1 Europe Alzheimer's Drugs Market Overview
9.3.2 Europe: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
9.3.2.1 Europe: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Drug Class
9.3.2.1.1 Europe: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Cholinesterase Inhibitors
9.3.2.2 Europe: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by End User
9.3.3 Europe: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Country
9.3.3.1 Germany: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3.3.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Drug Class
9.3.3.1.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.3.3.1.2 Germany: Alzheimer's Drugs Market Breakdown, by End User
9.3.3.2 United Kingdom: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3.3.2.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Drug Class
9.3.3.2.1.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.3.3.2.2 United Kingdom: Alzheimer's Drugs Market Breakdown, by End User
9.3.3.3 France: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3.3.3.1 France: Alzheimer's Drugs Market Breakdown, by Drug Class
9.3.3.3.1.1 France: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.3.3.3.2 France: Alzheimer's Drugs Market Breakdown, by End User
9.3.3.4 Italy: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3.3.4.1 Italy: Alzheimer's Drugs Market Breakdown, by Drug Class
9.3.3.4.1.1 Italy: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.3.3.4.2 Italy: Alzheimer's Drugs Market Breakdown, by End User
9.3.3.5 Spain: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3.3.5.1 Spain: Alzheimer's Drugs Market Breakdown, by Drug Class
9.3.3.5.1.1 Spain: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.3.3.5.2 Spain: Alzheimer's Drugs Market Breakdown, by End User
9.3.3.6 Rest of Europe: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3.3.6.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Drug Class
9.3.3.6.1.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.3.3.6.2 Rest of Europe: Alzheimer's Drugs Market Breakdown, by End User
9.4 Asia Pacific
9.4.1 Asia Pacific Alzheimer's Drugs Market Overview
9.4.2 Asia Pacific: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
9.4.2.1 Asia Pacific: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Drug Class
9.4.2.1.1 Asia Pacific: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Cholinesterase Inhibitors
9.4.2.2 Asia Pacific: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by End User
9.4.3 Asia Pacific: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Country
9.4.3.1 China: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4.3.1.1 China: Alzheimer's Drugs Market Breakdown, by Drug Class
9.4.3.1.1.1 China: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.4.3.1.2 China: Alzheimer's Drugs Market Breakdown, by End User
9.4.3.2 Japan: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4.3.2.1 Japan: Alzheimer's Drugs Market Breakdown, by Drug Class
9.4.3.2.1.1 Japan: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.4.3.2.2 Japan: Alzheimer's Drugs Market Breakdown, by End User
9.4.3.3 India: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4.3.3.1 India: Alzheimer's Drugs Market Breakdown, by Drug Class
9.4.3.3.1.1 India: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.4.3.3.2 India: Alzheimer's Drugs Market Breakdown, by End User
9.4.3.4 Australia: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4.3.4.1 Australia: Alzheimer's Drugs Market Breakdown, by Drug Class
9.4.3.4.1.1 Australia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.4.3.4.2 Australia: Alzheimer's Drugs Market Breakdown, by End User
9.4.3.5 South Korea: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4.3.5.1 South Korea: Alzheimer's Drugs Market Breakdown, by Drug Class
9.4.3.5.1.1 South Korea: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.4.3.5.2 South Korea: Alzheimer's Drugs Market Breakdown, by End User
9.4.3.6 Rest of APAC: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4.3.6.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Drug Class
9.4.3.6.1.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.4.3.6.2 Rest of APAC: Alzheimer's Drugs Market Breakdown, by End User
9.5 Middle East and Africa
9.5.1 Middle East and Africa Alzheimer's Drugs Market Overview
9.5.2 Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
9.5.2.1 Middle East and Africa: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Drug Class
9.5.2.1.1 Middle East and Africa: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Cholinesterase Inhibitors
9.5.2.2 Middle East and Africa: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by End User
9.5.3 Middle East and Africa: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Country
9.5.3.1 Saudi Arabia: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.5.3.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Drug Class
9.5.3.1.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.5.3.1.2 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by End User
9.5.3.2 South Africa: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.5.3.2.1 South Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
9.5.3.2.1.1 South Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.5.3.2.2 South Africa: Alzheimer's Drugs Market Breakdown, by End User
9.5.3.3 United Arab Emirates: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.5.3.3.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Drug Class
9.5.3.3.1.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.5.3.3.2 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by End User
9.5.3.4 Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.5.3.4.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
9.5.3.4.1.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.5.3.4.2 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by End User
9.6 South and Central America
9.6.1 South and Central America Alzheimer's Drugs Market Overview
9.6.2 South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
9.6.2.1 South and Central America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Drug Class
9.6.2.1.1 South and Central America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Cholinesterase Inhibitors
9.6.2.2 South and Central America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by End User
9.6.3 South and Central America: Alzheimer's Drugs Market – Revenue and Forecast Analysis – by Country
9.6.3.1 Brazil: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.6.3.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Drug Class
9.6.3.1.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.6.3.1.2 Brazil: Alzheimer's Drugs Market Breakdown, by End User
9.6.3.2 Argentina: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.6.3.2.1 Argentina: Alzheimer's Drugs Market Breakdown, by Drug Class
9.6.3.2.1.1 Argentina: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.6.3.2.2 Argentina: Alzheimer's Drugs Market Breakdown, by End User
9.6.3.3 Rest of South and Central America: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.6.3.3.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Drug Class
9.6.3.3.1.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
9.6.3.3.2 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by End User
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.2 Company Market Share Analysis, 2024
11. Industry Landscape
11.1 Overview
11.2 New Product Development and Approvals
11.3 Partnerships
11.4 Other Business Strategies
12. Company Profiles
12.1 Novartis AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Daiichi Sankyo Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Johnson & Johnson
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Pfizer Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Merck & Co Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Biogen Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merz Pharma GmbH & Co KGaA
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Eli Lilly and Co
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Otsuka Pharmaceuticals Co Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 AbbVie Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Alzheimer's Drugs Market Segmentation
Table 2. Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million)
Table 3. Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million)
Table 4. North America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 5. North America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 6. North America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 7. North America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 8. North America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 9. North America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 10. United States: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 11. United States: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 12. United States: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 13. United States: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 14. United States: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 15. United States: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 16. Canada: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 17. Canada: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 18. Canada: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 19. Canada: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 20. Canada: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 21. Canada: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 22. Mexico: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 23. Mexico: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 24. Mexico: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 25. Mexico: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 26. Mexico: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 27. Mexico: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 28. Europe: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 29. Europe: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 30. Europe: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 31. Europe: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 32. Europe: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 33. Europe: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 34. Germany: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 35. Germany: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 36. Germany: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 37. Germany: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 38. Germany: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 39. Germany: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 40. United Kingdom: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 41. United Kingdom: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 42. United Kingdom: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 43. United Kingdom: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 44. United Kingdom: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 45. United Kingdom: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 46. France: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 47. France: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 48. France: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 49. France: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 50. France: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 51. France: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 52. Italy: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 53. Italy: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 54. Italy: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 55. Italy: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 56. Italy: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 57. Italy: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 58. Spain: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 59. Spain: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 60. Spain: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 61. Spain: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 62. Spain: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 63. Spain: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 64. Rest of Europe: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 65. Rest of Europe: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 66. Rest of Europe: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 67. Rest of Europe: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 68. Rest of Europe: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 69. Rest of Europe: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 70. Asia Pacific: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 71. Asia Pacific: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 72. Asia Pacific: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 73. Asia Pacific: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 74. Asia Pacific: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 75. Asia Pacific: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 76. China: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 77. China: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 78. China: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 79. China: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 80. China: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 81. China: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 82. Japan: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 83. Japan: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 84. Japan: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 85. Japan: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 86. Japan: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 87. Japan: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 88. India: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 89. India: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 90. India: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 91. India: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 92. India: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 93. India: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 94. Australia: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 95. Australia: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 96. Australia: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 97. Australia: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 98. Australia: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 99. Australia: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 100. South Korea: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 101. South Korea: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 102. South Korea: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 103. South Korea: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 104. South Korea: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 105. South Korea: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 106. Rest of APAC: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 107. Rest of APAC: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 108. Rest of APAC: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 109. Rest of APAC: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 110. Rest of APAC: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 111. Rest of APAC: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 112. Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 113. Middle East and Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 114. Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 115. Middle East and Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 116. Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 117. Middle East and Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 118. Saudi Arabia: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 119. Saudi Arabia: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 120. Saudi Arabia: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 121. Saudi Arabia: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 122. Saudi Arabia: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 123. Saudi Arabia: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 124. South Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 125. South Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 126. South Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 127. South Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 128. South Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 129. South Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 130. United Arab Emirates: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 131. United Arab Emirates: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 132. United Arab Emirates: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 133. United Arab Emirates: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 134. United Arab Emirates: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 135. United Arab Emirates: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 136. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 137. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 138. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 139. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 140. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 141. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 142. South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 143. South and Central America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 144. South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 145. South and Central America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 146. South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 147. South and Central America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 148. Brazil: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 149. Brazil: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 150. Brazil: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 151. Brazil: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 152. Brazil: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 153. Brazil: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 154. Argentina: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 155. Argentina: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 156. Argentina: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 157. Argentina: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 158. Argentina: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 159. Argentina: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 160. Rest of South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 161. Rest of South and Central America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 162. Rest of South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by Cholinesterase Inhibitors
Table 163. Rest of South and Central America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Cholinesterase Inhibitors
Table 164. Rest of South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2024 (US$ Million) – by End User
Table 165. Rest of South and Central America: Alzheimer's Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by End User
Table 166. Heat Map Analysis by Key Players
Table 167. Glossary of Terms, Global Alzheimer's Drugs Market
LIST OF FIGURES
Figure 1. Alzheimer's Drugs Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Alzheimer's Drugs Market Revenue (US$ Million), 2021–2031
Figure 5. Alzheimer's Drugs Market Share (%) – by Drug Class (2024 and 2031)
Figure 6. Cholinesterase Inhibitors: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. NMDA Receptor Antagonists: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Combination Drugs: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Others: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Alzheimer's Drugs Market Share (%) – by End User (2024 and 2031)
Figure 11. Hospital Pharmacies: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Retail Pharmacies: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Online Pharmacies: Alzheimer's Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Alzheimer's Drugs Market Breakdown by Region, 2024 and 2031 (%)
Figure 15. North America: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 16. North America: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 17. United States: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 18. Canada: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 19. Mexico: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. Europe: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 21. Europe: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 22. Germany: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 23. United Kingdom: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 24. France: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 25. Italy: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 26. Spain: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 27. Rest of Europe: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 28. Asia Pacific: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 29. Asia Pacific: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 30. China: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 31. Japan: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 32. India: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 33. Australia: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 34. South Korea: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 35. Rest of APAC: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 36. Middle East and Africa: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 37. Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 38. Saudi Arabia: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 39. South Africa: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 40. United Arab Emirates: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 41. Rest of Middle East and Africa: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 42. South and Central America: Alzheimer's Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 43. South and Central America: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 44. Brazil: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 45. Argentina: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 46. Rest of South and Central America: Alzheimer's Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 47. Company Market Share Analysis, 2024
The List of Companies - Alzheimer’s Drugs Market
- Novartis AG
- Daiichi Sankyo Co Ltd
- Johnson & Johnson
- Pfizer Inc.
- Merck & Co Inc
- Biogen Inc
- Merz Pharma GmbH & Co KGaA
- Eli Lilly and Co
- Otsuka Pharmaceuticals Co Ltd
- AbbVie Inc.
- Eisai Co., Ltd
- AstraZeneca PLC
- H. Lundbeck A/S
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd
- Alzheon Inc.
- Anavex Life Sciences Corp.
- Cassava Sciences Inc.
- Avid Radiopharmaceuticals
- Alnylam Pharmaceuticals
- Alector Therapeutics
- Karuna Therapeutics
- AC Immune SA
- Denali Therapeutics Inc.
- Athira Pharma Inc.
- TauRx Therapeutics Ltd.